Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Trabectedin +/- Carboplatin in Recurrent Ovarian Cancer
NCT01735071Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jul 2013
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trabectedin and bevacizumab in ovarian epithelial cancer (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Progression Free Survival at 6 months and Proportion of patients with severe toxicity at 6 months. Started Jul 2013; status: completed.
02
Drugs
trabectedinbevacizumab
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT01735071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01735071.